Methods Inf Med 2010; 49(05): 458-461
DOI: 10.3414/ME09-02-0032
Special Topic – Original Articles
Schattauer GmbH

Sleep Stage Transitions in Healthy Humans Altered by Central Monoaminergic Antagonist

A. Kishi
1   Educational Physiology Laboratory, Graduate School of Education, The University of Tokyo, Tokyo, Japan
2   Japan Society for the Promotion of Science, Tokyo, Japan
,
H. Yasuda
3   Department of Psychiatry, Shimane University School of Medicine, Izumo, Shimane, Japan
,
T. Matsumoto
4   Seiwakai Nishikawa Hospital, Hamada, Shimane, Japan
,
Y. Inami
5   Department of Psychiatry, Ehime Rosai Hospital, Niihama, Ehime, Japan
,
J. Horiguchi
3   Department of Psychiatry, Shimane University School of Medicine, Izumo, Shimane, Japan
,
Z. R. Struzik
1   Educational Physiology Laboratory, Graduate School of Education, The University of Tokyo, Tokyo, Japan
,
Y. Yamamoto
1   Educational Physiology Laboratory, Graduate School of Education, The University of Tokyo, Tokyo, Japan
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received: 02. Oktober 2009

accepted: 12. Mai 2009

Publikationsdatum:
17. Januar 2018 (online)

Preview

Summary

Objectives: Sleep stage transitions constitute one of the key components of the dynamical aspect of sleep. However, neural mechanisms of sleep stage transitions have not, to date, been fully elucidated. We investigate the effects of administrating risperi-done, a central serotonergic and dopaminergic antagonist, on sleep stage transitions inhumans, and also on ultradian rapid-eye-movement (REM) sleep rhythms.

Methods: Ten healthy young male volunteers (age: 22 ± 3.7 years) participated in this study. The subjects spent three nights in a sleep laboratory. The first was the adaptation night, and the second was the baseline night. On the third night, the subjects received risperidone (1 mg tablet) 30 min before the polysomnography recording. We measured and investigated transition probabilities between waking, REM and non-REM (stages I–IV) sleep stages.

Results: We found that the probability of transition from stage II to stage III was significantly greater for the risperidone night than for the baseline night. We also found that risperidone administration prolonged REM-onset intervals, when compared to the baseline night.

Conclusions: We demonstrate that central serotonergic and /or dopaminergic neural transmissions are involved in the regulation of sleep stage transitions from light (stage II) to deep (stage III) sleep, and also in determining ultradian REM sleep rhythms.